Reaction
Adenocarcinoma Gastric reporting signals
As of the last recalculation, Adenocarcinoma Gastric appears in 909 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is SUCRALFATE ORAL (PRR 38.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sucralfate Oral | 23 | 38.0 | 38.0 |
| Sucralfate Oral Suspension | 23 | 37.9 | 37.9 |
| Sucralfate | 32 | 31.7 | 31.7 |
| Cimetidine | 10 | 24.0 | 24.1 |
| Polyethylene Glycol | 11 | 23.5 | 23.6 |
| Hyoscyamine Sulfate | 9 | 22.7 | 22.7 |
| Trastuzumab | 49 | 17.2 | 17.2 |
| Dronabinol | 6 | 17.2 | 17.2 |
| Esomeprazole Magnesium | 146 | 16.8 | 16.8 |
| Baricitinib | 7 | 16.7 | 16.8 |
| Ado-Trastuzumab Emtansine | 6 | 16.4 | 16.4 |
| Melphalan | 16 | 16.4 | 16.4 |
| Oxaliplatin | 50 | 16.3 | 16.3 |
| Benzonatate | 11 | 15.4 | 15.4 |
| Melphalan Hydrochloride | 16 | 14.9 | 14.9 |
| Cisplatin | 48 | 14.8 | 14.8 |
| Fluorouracil Cream, 0.5% | 45 | 14.2 | 14.2 |
| Fluorouracil | 45 | 14.0 | 14.0 |
| Terbinafine Hydrochloride | 5 | 13.0 | 13.0 |
| Imatinib | 9 | 11.8 | 11.8 |
| Prochlorperazine | 14 | 11.7 | 11.7 |
| Brentuximab Vedotin | 5 | 11.2 | 11.2 |
| Iohexol | 4 | 11.1 | 11.1 |
| Ifosfamide | 10 | 10.8 | 10.8 |
| Bendamustine Hydrochloride | 5 | 9.6 | 9.6 |
| Vemurafenib | 4 | 7.6 | 7.7 |
| Obinutuzumab | 5 | 7.0 | 7.0 |
| Durvalumab | 6 | 6.8 | 6.8 |